Industry news that matters to you.  Learn more

Archives for October 2010

Lilly to Close Singapore Discovery Center

Eli Lilly will be closing the Lilly Singapore Centre for Drug Discovery by the end of the year, according to an email sent out this morning by Jonathon Sedgwick, Managing Director & Chief Scientific Officer, Lilly Singapore Centre for Drug Discovery (LSCDD).

Exagen Buys Cypress’ Diagnostics Business

Exagen Diagnostics Inc. acquired the medical diagnostics division of Cypress Bioscience Inc. in San Diego, Calif.

Research Universities and Big Pharma’s Wicked Problem

A few years ago BP awarded a consortium of universities led by Berkeley the largest grant in University of California history: $500 million over ten years to develop biofuels. Despite BP’s well-publicized travails, their commitment to the Energy Biosciences Institute remains firmly in place.

Urine Protein Could Pave the Way for New Prostate Cancer Test

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

Scientists from the Cancer Research UK Cambridge Research Institute and The Institute of Cancer Research (ICR) built on earlier genome-wide research to link a genetic change associated with prostate cancer risk to a significant reduction in the amount of a protein called microseminoprotein-beta (MSMB). The protein – which regulates prostate cell death – is produced by normal prostate cells – and is linked to an increased risk of developing prostate cancer.

Panel Calls for Biomarkers in Routine Clinical AD Diagnosis

Clinicians should try to incorporate biomarker data in their diagnosis of patients with Alzheimer’s disease or conditions potentially leading to it, an ad hoc expert panel recommended.

Levels of beta-amyloid or tau proteins in cerebrospinal fluid (CSF), or data from MRI or PET scans using amyloid-specific tracers, should be part of the differential diagnosis of Alzheimer-related disorders, according to two dozen members of the International Working Group for New Research Criteria for the Diagnosis of Alzheimer’s Disease.